1. Home
  2. GORO vs IFRX Comparison

GORO vs IFRX Comparison

Compare GORO & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gold Resource Corporation

GORO

Gold Resource Corporation

HOLD

Current Price

$1.32

Market Cap

250.9M

ML Signal

HOLD

Logo InflaRx N.V.

IFRX

InflaRx N.V.

HOLD

Current Price

$0.95

Market Cap

60.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GORO
IFRX
Founded
1998
2007
Country
United States
Germany
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
250.9M
60.6M
IPO Year
2010
2017

Fundamental Metrics

Financial Performance
Metric
GORO
IFRX
Price
$1.32
$0.95
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
6
Target Price
$1.75
$8.50
AVG Volume (30 Days)
2.0M
171.7K
Earning Date
04-16-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$65,726,000.00
N/A
Revenue This Year
$9.04
N/A
Revenue Next Year
$93.07
$1,054.36
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.34
$0.71
52 Week High
$1.87
$1.94

Technical Indicators

Market Signals
Indicator
GORO
IFRX
Relative Strength Index (RSI) 41.73 52.69
Support Level $1.27 $0.75
Resistance Level $1.75 $1.16
Average True Range (ATR) 0.10 0.07
MACD -0.03 0.01
Stochastic Oscillator 1.75 50.85

Price Performance

Historical Comparison
GORO
IFRX

About GORO Gold Resource Corporation

Gold Resource Corp is a producer of metal concentrates that contain gold, silver, copper, lead, and zinc in Oaxaca, Mexico. . It targets low capital expenditure projects with the potential for generating high returns on capital. The company's two pipeline projects are; Don David Gold at Oaxaca, Mexico, and Back Forty at Michigan, United States of America. The Company has two reporting segments, based on geographic regions. Oaxaca, Mexico represents the Company's only operating segment with a production stage property. The Company's other reporting segment is Michigan, U.S.A., with an exploration stage property.

About IFRX InflaRx N.V.

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: